Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 289.60
+8.20 (2.91%)
Jun 30, 2026, 4:59 PM CET
Zealand Pharma Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Zealand Pharma stock has a consensus rating of "Buy" and an average price target of kr 457.57. The average 1-year stock price forecast is 58.00% higher than the current stock price, while the lowest is kr 300.00 (+3.59%) and the highest is kr 745.00 (+157.25%).
Price Target: kr 457.57 (+58.00%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Zealand Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 8 | 8 | 8 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 5 | 5 | 5 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 17 | 17 | 17 |
Financial Forecast
Revenue This Year
4.61B
from 9.21B
Decreased by -49.95%
Revenue Next Year
4.27B
from 4.61B
Decreased by -7.41%
EPS This Year
22.07
from 90.22
Decreased by -75.53%
EPS Next Year
7.73
from 22.07
Decreased by -64.99%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is DKK.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.0B | ||
| Avg | 4.6B | ||
| Low | 3.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -45.4% | ||
| Avg | -49.9% | ||
| Low | -63.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 32.30 | ||
| Avg | 22.07 | ||
| Low | 7.51 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -64.2% | ||
| Avg | -75.5% | ||
| Low | -91.7% |